| Date Joined: | 1997 |
| Board Seats: | Ascenta Therapeutics, Century Hospice, diaDexus, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix |
| Focus: | Healthcare |
| Past: | Gilead Sciences – Director, Corporate Development and Sales Representative |
| Education: | California State University, San Francisco – M.B.A. in Finance |
Lou focuses on identifying emerging biopharmaceutical, device and platform technology companies. He sits on the Boards of Ascenta Therapeutics, Century Hospice, diaDexus, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVP’s investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).
Lou joined ScaleVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead’s approved antiviral drug, Vistide, and was responsible for the discovery of Gilead’s novel thrombin aptamer. Prior to Gilead, he was a research associate at Genentech.
Lou holds an M.B.A. in Finance from California State University, San Francisco and a B.S. in Biology from California State University, Chico.
- Duexis now approved by FDA!! yhoo.it/hFSeVq
- interesting article this wkend. "Analyst Report" on america written by Mary Meeker tinyurl.com/4rty8kb and scr.bi/ejXpkw
- meant to add the link to the wsj editorial on.wsj.com/heDydp
-
Scale Venture PartnersNovember 8, 2011
-
XconomyJanuary 10, 2011
-
Venture Capital JournalApril 1, 2010
-
Seeking AlphaJanuary 3, 2012
-
BloombergSeptember 20, 2011
-
ReutersAugust 17, 2011
